Zacks Investment Research upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong sell rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. Zacks Investment Research currently has $23.00 price target on the specialty pharmaceutical company’s stock.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
Several other research firms have also commented on COLL. HC Wainwright lowered their price objective on shares of Collegium Pharmaceutical from $33.00 to $28.00 and set a buy rating for the company in a research report on Friday, August 6th. Needham & Company LLC initiated coverage on shares of Collegium Pharmaceutical in a research report on Friday, September 17th. They set a buy rating and a $32.00 price objective for the company. Finally, Cantor Fitzgerald lowered shares of Collegium Pharmaceutical from an overweight rating to a neutral rating and lowered their target price for the stock from $30.00 to $22.00 in a report on Friday, August 6th.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, August 5th. The specialty pharmaceutical company reported $0.27 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.34 by ($0.07). The company had revenue of $82.94 million for the quarter, compared to analysts’ expectations of $84.29 million. Collegium Pharmaceutical had a net margin of 32.73% and a return on equity of 22.59%. On average, equities research analysts forecast that Collegium Pharmaceutical will post 1.38 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of COLL. Captrust Financial Advisors acquired a new stake in Collegium Pharmaceutical in the 1st quarter worth approximately $27,000. PNC Financial Services Group Inc. lifted its stake in Collegium Pharmaceutical by 245.9% during the 2nd quarter. PNC Financial Services Group Inc. now owns 1,266 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 900 shares during the period. Royal Bank of Canada lifted its stake in Collegium Pharmaceutical by 344.3% during the 2nd quarter. Royal Bank of Canada now owns 3,110 shares of the specialty pharmaceutical company’s stock valued at $74,000 after acquiring an additional 2,410 shares during the period. Shell Asset Management Co. acquired a new stake in Collegium Pharmaceutical during the 1st quarter valued at approximately $99,000. Finally, Ensign Peak Advisors Inc acquired a new stake in Collegium Pharmaceutical during the 1st quarter valued at approximately $102,000.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR.
See Also: What is a resistance level?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.